Alopecia Areata Video Perspectives
Emma Guttman-Yassky, MD, PhD
Disclosures
Guttman-Yassky reports financial relationships with AbbVie, Almirall, Amgen, AnaptysBio, Arena, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Innovaderm, Janssen Biotech, Kyowa Kirin, LEO Pharma, Novartis, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB and Ventyx Biosciences.
October 11, 2023
1 min watch
Save
VIDEO: Alopecia areata research should focus on new treatment targets
Transcript
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Definitely we need more research into the disease to identify new targets because now we have the JAK inhibitors, but I think we need new targets so we have more medications in general, including oral medications, so small molecules, but also biologics and I think that comes from increased knowledge.
